Abstract
Accumulating evidence indicates that mitochondria have a key role in non-alcoholic fatty liver disease (NAFLD). C57BL/6J mice were fed a choline-deficient, ethionine-supplemented (CDE) diet. Histological studies demonstrated accumulation of fat vacuoles in up to 90% of hepatocytes in mice fed the CDE diet for 14 days. In addition, a decrease in mitochondrial levels, together with an increase in superoxide radicals’ levels were observed, indicating elevation of oxidative stress in hepatocytes. ATP levels were decreased in livers from CDE-fed mice after overnight fasting. This was accompanied by a compensative and significant increase in peroxisome-proliferator-activated receptor-γ coactivator 1α (PGC1α) mRNA levels in comparison to control livers. However, there was a reduction in PGC1α protein levels in CDE-treated mice. Moreover, the expression of mitochondrial biogenesis genes nuclear respiratory factor 1 (NRF-1), mitochondrial transcription factor A (TFAM), mitochondrial transcription factor B1 (TFB1M) and mitochondrial transcription factor B2 (TFB2M), which are all regulated by PGC1α activity, remained unchanged in fasted CDE-treated mice. These results indicate impaired activity of PGC1α. The impaired activity was further confirmed by chromatin immunoprecipitation analysis, which demonstrated decreased interaction of PGC1α with promoters containing NRF-1 and NRF-2 response elements in mice fed the CDE diet. A decrease in PGC1α ability to activate the expression of the gluconeogenic gene phosphoenol-pyruvate carboxykinase was also observed. This study demonstrates, for the first time, that attenuated mitochondrial biogenesis in steatotic livers is associated with impaired biological activity of PGC1α.
Similar content being viewed by others
Main
Non-alcoholic fatty liver disease (NAFLD) is becoming more common in Western countries. Non-alcoholic steatohepatitis (NASH) is found in a subset of NAFLD patients who have, in addition to excess fat, evidence of characteristic hepatocellular injury and necro-inflammatory changes.1 Wanless and Lentz2 found steatosis in 70% of obese and 35% of lean patients in a consecutive autopsy study. Among obese patients, the prevalence of simple steatosis is about 60%, whereas NASH is found in 20–25% of all subjects.3
Fatty liver is found in most men and postmenopausal women when deprived of dietary choline.4 Choline is a precursor of the membrane phospholipid phosphatidylcholine, which is required for the release of very low-density lipoprotein from the liver. In animal models, choline-deficient (CD) diet leads to an increase in liver triglyceride content and development of NAFLD. If the diet continues, the liver develops NASH, fibrosis, and cirrhosis, with some animals progressing to hepatocellular carcinoma.5 It was found that liver injury is more severe when adequate levels of folate and methionine are lacking during a CD diet.6 Therefore, we have used in the current study a model of choline deficiency and ethionine, a methabolic antagonist of methionine, supplemented diet (CDE diet), which represents steatosis and liver injury.7, 8, 9
There is accumulating evidence that mitochondria have a key role in NAFLD.10, 11 Mitochondria have many functions in the cell, including β-oxidation, regulation of cell viability and death, and creating ATP in the oxidative phosphorylation machinery.12 Superoxide radicals (O2•−), generated in the mitochondria as a by-product of the respiratory chain process, can be further transformed into different reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) and hydroxyl radicals.13 Mitochondrial abnormalities related to an increased generation of ROS have been described in human steatosis of various etiology and in several experimental models of fatty liver, including alcohol administration and drug toxicity.14
An important coactivator in liver biology is peroxisome-proliferator-activated receptor-γ coactivator 1α (PGC1α).15 Induction of this coactivator has been documented in experimental models of obesity and diabetes.16 Activation of PGC1α results in increased expression of genes important to gluconeogenesis, fatty acid oxidation, lipid transport and mitochondrial biogenesis processes.17, 18, 19, 20 The mitochondrial biogenesis process involves expression of nuclear-encoded proteins that are essential for the replication of mitochondrial DNA (mtDNA) and the expression of mtDNA-encoded genes.21 PGC1α also has a role in this metabolic pathway by activating mitochondrial nuclear respiratory factor 1 (NRF-1) and NRF-2 to induce expression of mitochondrial transcription factor A (TFAM). TFAM is important to the stability and the transcription of mtDNA.22, 23 Falkenberg et al24 identified two additional transcription factors, which are necessary for basal transcription of mtDNA: mitochondrial transcription factor B1 (TFB1M) and B2 (TFB2M) (tfb1m and tfb2m in mice). Apparently, the expression of these two proteins (TFBMs) is regulated by the complexes PGC1α–NRF-1 and PGC1α–NRF-2.25
The goal of the study is to demonstrate impairment in mitochondrial biogenesis during the development of fatty liver disease. We focused on the association between the mitochondrial biogenesis process and the biological activity of PGC1α in CDE-treated mice as a model of steatosis and liver injury.
MATERIALS AND METHODS
Animals
Four- to five-week-old male mice of the C57BL/6J inbred strain (purchased from Harlen Laboratories, Israel) were treated with a CDE diet as previously described.7, 8, 9 Following 14 days on the CDE diet, animals were sacrificed with or without overnight fasting, serum was collected and livers were perfused with PBS to remove blood traces. Liver portions were snap frozen in liquid nitrogen, and kept at −80°C for further processing. All animals were cared for under the guidelines set forth by the Animal Care and Use Committee of the Hebrew University of Jerusalem.
Liver Histology
Hepatic steatosis and liver structural changes were assessed by histological evaluation. Removed livers were fixed in 4% formaldehyde (Bio-Lab, Israel) and 5 μm of microtome sections (Leica Microsystems, Wetzlar, Germany) were collected. Hematoxylin–eosin (Sigma-Aldrich, St Louis, MO, USA) staining was used for tissue section visualization. Data were collected from two livers from different mice for each time point. For quantification, cells with fat droplets that are bigger than the nucleus were counted. The percentage of cells-containing fat was determined in comparison to control.
Cell Line
Mouse hepatocyte AML-12 cells were grown as described previously.9 Cells were exposed to 10 μg/ml oligomycin (O-4786; Sigma-Aldrich) for 6 h.
Western Blot
Western blots were performed as described previously.26 Primary antibodies used: mouse monoclonal anti-NDUFA9, Anti-PGC1α (ab54481), anti-CoxIV (Abcam, Cambridge, UK), mouse anti-manganese superoxide dismutase (anti-MnSOD) (BD Biosciences, Franlkin Lakes, NJ, USA). Mouse anti-β-actin (BD Transduction Laboratories, Pharmigen, CA, USA) was used as an endogenous control. Secondary antibodies used: horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit (Jackson ImmunoResearch Laboratories, PA, USA). Protein levels were quantified using Gel-Pro Analyzer, version 4.0 (Media Cybernetics, Bethesda, MD, USA).
Quantitative Real-Time Polymerase Chain Reaction
QRT–PCR technique was preformed according to a published procedure.27 18S was used as the endogenous control. The list of the primers for all genes can be found in the supplementary data.
mtDNA Quantification
Total DNA was isolated from control and CDE-fed mice using a kit (Promega, Madison, WI, USA). The mtDNA content relative to nuclear DNA was assessed by QRT–PCR by using 20 ng of total DNA as template and primers for mtCO1 (mitochondrial genome) and RIP140 (nuclear genome).28, 29
β-Hydroxybutyrate Levels
Generation of β-hydroxybutyrate was evaluated in serum samples of mice fed with a control or a CDE diet for 14 days, followed by 48 h of fasting. β-Hydroxybutyrate concentration was determined using a kit (Cat. No. 700190, Cayman Chemical Company, MI, USA) according to the manufacturer's instructions.
ROS Measurement
Superoxide levels were detected using dihydroethidium (DHE; Molecular Probes, Eugene, OR, USA). Livers cryosections (20 μm) from snap frozen liver portions (left lateral lobe) were obtained using a Reichert-Jung 2800 Frigocut cryostat (Cambridge Instruments, Nussloch, Germany). Cryosections were stained with 10 μM DHE at 37°C for 30 min. Superoxide levels are demonstrated by red fluorescent labeling.30 Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, MP Biomedicals, Solon, OH, USA).
ATP Measurement
ATP levels in liver or in cell-culture samples were determined using FLE enzyme (F3641; Sigma-Aldrich) in a luminometer according to the manufacturer's instructions.
Chromatin Immunoprecipitation Analysis
The chromatin immunoprecipitation (ChiP) assay was carried out using a kit (Cat. No. P-2003, Epigentek, NY, USA). Briefly, 50 mg of liver tissue samples was cut into small pieces and cross-linked with 1% formaldehyde for 20 min. After homogenization, the samples were sonicated (Vibra Cell, Sonics, CT, USA) for 20 × 10 s at 20% of maximum power to produce a soluble chromatin, with average sizes between 300 and 1000 bp. In all, 8 mg of the sonicated chromatin were exposed to anti-PGC1α antibody (SC-13067, Santa Cruz Biotechnology), anti-RNA Polymerase II (positive control), or to rabbit IgG antibody (negative control). Subsequent incubation and washes were completed according to the manufacturer's instructions. In all, 2 μl of DNA was used for each QRT–PCR, which was performed as described before.27 The data were analyzed using the function 2−ΔΔCT where ΔΔCT=(CT, IP−CT, input)sample−(CT, IP−CT, input)calibrator. As calibrators, primers were designed to a distal region of the different promoters. Relative promoter enrichment compared with negative control are presented.31, 32
Statistical Analysis
Data were collected from 12 mice in each treatment group from at least two independent experiments. All values are expressed as mean values+s.e. Comparisons between two groups were performed with Student's t-test. For multiple groups, data were analyzed by analysis of variance. Differences were considered significant at probability levels of P<0.05 by using the Fisher's protected least significant difference method. Statistical analysis was performed by using the statistical computer program, SPSS version 11 (SPSS, Chicago, IL, USA). In experiments with multiple groups we used common letters in order to indicate significance. The highest average in each experiment was marked with the letter ‘a’. The next (lower) significant average was marked with the letter ‘b’ etc. Means with different letters are significantly different at P<0.05.
RESULTS
Development of Steatosis in CDE-Fed Mice
Histological sections demonstrated accumulation of fat vacuoles in up to 90% of hepatocytes in mice fed the CDE diet for 14 days, as can be seen in the representative pictures and in the quantitative graph that represents the percentage of fat-containing cells at different time points (Figure 1). These results corroborate previously reported data from our laboratory that demonstrated an increase in total liver lipid content and increased liver injury in CDE-treated mice.9 At day 21, there was a moderate reduction in liver fat content compared with day 14. Replacement of the CDE diet with a control diet after 21 days for additional 6 days decreased fat content in the liver to control levels, with increased mitosis rate, suggesting hepatocellular regeneration (data not shown).
Mitochondrial Levels in Mice Fed the CDE Diet for 14 Days
We studied changes in different mitochondrial parameters in livers from mice that were fed control or CDE diet for 14 days. A significant reduction in the protein levels of the mitochondrial electron transport chain proteins NADH dehydrogenase (ubiquinone) 1 α subcomplex, 9 (NDUFA9, subunit of complex I) and cytochrome c oxidase IV (Cox IV, subunit of complex IV) was observed (Figure 2a), suggesting a decrease in mitochondrial levels in CDE-fed mice. This was confirmed in quantitative measurements of mitochondrial levels, which indicated a 50% reduction in mtDNA copies in livers from CDE-fed mice, when compared with control-fed mice (Figure 2b). Levels of β-hydroxybutyrate (a ketone body) were measured in serum samples in order to evaluate the efficiency of hepatic fatty oxidation process.33 β-Hydroxybutyrate concentration following 48 h fasting was significantly lower in the serum of CDE-fed mice when compared with control-fed mice, demonstrating decreased capacity for ketone body formation (Figure 2c).
Oxidative Stress
Staining liver cryosections with DHE revealed increased levels of superoxide radicals after 14 days with the CDE diet (Figure 3b). Measurement of MnSOD levels, an antioxidant enzyme in the mitochondria that is responsible for the dismutation of superoxide radicals into hydrogen peroxide34 was also carried out. Reduced mRNA and protein levels of MnSOD were found in livers from mice fed with the CDE diet (Figure 3a). This positively correlated with the decrease in NDUFA9 and Cox IV protein levels (Figure 2a). These results demonstrate that changes in redox status in hepatocytes containing excessive amounts of fat lead to increased oxidative stress in the liver.
Reduction in ATP Production and Activation of PGC1α by the CDE Diet
In order to explore whether the decrease in mitochondrial levels and the increase in oxidative stress impairs ATP production, ATP levels were measured in liver extracts following 14 days on the CDE diet. Levels of ATP were determined at the end point of the experiment in both mice that had a free access to food and in mice following an overnight fast. In the fed state, the CDE diet led to a small but non-significant decrease in ATP levels. However, following an overnight fast, ATP levels were significantly lower in CDE-fed mice when compared with control mice (Figure 4a).
The effect of fasting on mitochondrial parameters in CDE-fed mice was evaluated with regard to energy expenditure pathways. mRNA levels of PGC1α were evaluated. Surprisingly, in the fed state there was no effect of CDE diet on PGC1α expression when compared with control livers (Figure 4b). After overnight fasting, however, CDE diet led to a significant increase in the mRNA levels of PGC1α when compared with control mice. It is probable that this increase is an attempt to compensate for the decline in mitochondrial tissue content.
A direct connection between the upregulation of PGC1α and the downregulation in ATP levels was sought using mouse AML-12 hepatocytes cell line. ATP levels in CDE versus control livers were found to be inversely correlated to the mRNA levels of PGC1α. AML-12 hepatocytes were treated with oligomycin, an inhibitor of ATP synthase, in order to reduce cellular ATP levels (Figure 4c). As can be seen in Figure 4d, the reduction in ATP levels was accompanied by a significant increase in PGC1α mRNA levels, indicating a direct link between the capacity of mitochondria to produce ATP and the expression of PGC1α.
Effect of CDE Diet on Mitochondrial Biogenesis
Although there was no significant change in PGC1α mRNA levels in steatotic livers in the fed state (Figure 4b), a 50% reduction in the protein levels of PGC1α was found (Figure 5a). This was accompanied by a 30% decrease in the mRNA levels of PGC1α-target genes NRF-1 and TFAM (Figure 5b and c). Furthermore, the significant increase in the mRNA levels of PGC1α in steatotic livers after overnight fasting, did not lead to an increase in its protein levels, or to a change in the levels of NRF-1 and TFAM when compared with control livers (Figure 5b and c). NRF-2 is also an important transcription factor in the mitochondrial biogenesis process, yet its expression is not regulated by PGC1α activity.23 In contrast to NRF-1 and TFAM expression, the mRNA levels of NRF-2 did not change in steatotic livers when compared with control livers, while overnight fasting, with or without CDE diet, led to an increase in NRF-2 mRNA levels (Figure 5d). This demonstrates that the effect of steatosis is specific to genes whose expression is regulated by the coactivator PGC1α.
Impaired PGC1α Biological Activity in Livers of CDE-Fed Mice
mRNA levels of the mouse PGC1α-target genes tfb1m and tfb2m were measured in liver samples. No change in the expression of tfb1m was found in livers of mice fed the CDE diet, while overnight fasting led to a decrease in its expression compared with the fed state (Figure 6a). The expression of tfb2m, however, decreased in steatotic livers when compared with control livers (Figure 6b). The mRNA levels of phosphoenol-pyruvate carboxykinase (PEPCK) were also measured. PEPCK is an important gluconeogenic enzyme in the liver, whose expression is regulated by PGC1α-induced coactivation of the forkhead box O1 (FOXO1) transcription factor.35 The pattern of PEPCK expression resembled that of tfb2m (Figure 6c). Fasting in control animals led to an increase in both tfb2m and PEPCK expression, as expected (Figure 6b and c).
In order to further evaluate PGC1α activity, a ChiP assay was performed. ChiP analysis using anti-PGC1α antibody for immunoprecipitation provided information related to the binding of PGC1α-transcription factors complexes to tfb1m, tfb2m and PEPCK promoters in vivo. As can be seen in Figure 7, there was no change in the binding of the transcriptional complex to the promoter of tfb1m (Figure 7a). However, the binding of the complex to tfb2m was lower in steatotic livers when compared with control livers in the fed state (Figure 7b), which is consistent with the reduced protein levels of PGC1α (Figure 5a). Fasting induced a twofold increase in PGC1α activity, while the binding of the complex to the tfb2m promoter dropped dramatically in CDE-fed mice (Figure 7b). In addition, examining the binding of the complex PGC1α–FOXO1 to PEPCK promoter illustrated a fivefold increase in the transcriptional complex after overnight fasting (Figure 7c). Nevertheless, the accumulation of fat in the liver significantly decreased the binding of the complex to the promoter both in the fed and the fasted state (Figure 7c).
DISCUSSION
The present study examined the impact of steatosis on hepatocyte metabolism using the CDE-diet model in mice, focusing on mitochondrial biogenesis process. At day 14 from the beginning of the diet, accumulation of fat and generation of oxidative stress are demonstrated (Figures 1 and 3). These results are in accordance to Day and James ‘two hit’ proposed model for the development of NASH,14 in which steatosis in the ‘first hit’ is followed by oxidative stress in the ‘second hit’. It could be that the decrease in mitochondrial levels in steatotic livers (Figure 2) mediated the increase in ROS generation.13, 14 However, mitochondria could still effectively generate ATP in the fed state (Figure 4), while a reduction in ATP production was found only in livers of CDE-fed mice after overnight fasting (Figure 4). The significant decrease in ATP after fasting was accompanied by a reduction in the release of β-hydroxybutyrate from the liver (Figure 2), and also by reduced expression of PEPCK (Figure 6). Taken together, the data suggest that CDE reduced the capability of hepatocytes to utilize nutrients for energy, most probably by affecting cellular pathways that are related to PGC1α and energy expenditure, such as β-oxidation in the mitochondria, mitochondrial biogenesis, and the gluconeogenesis processes. It would be interesting to further evaluate the direct influence of the diet in isolated mitochondria.
As is shown in Figures 4b and 5a, the liver responses to fasting by increasing expression of PGC1α, a key transcriptional regulator of energy homeostasis. Similar results were reported previously by others.36, 37 Our both in vivo and in vitro results suggest that PGC1α transcription is a sensor for decreased ATP levels. In CDE-fed mice, overnight fasting, which decreased ATP levels, led to a significant increase in PGC1α expression (Figure 4b). Furthermore, in the mouse hepatocyte cell line AML-12, a direct reduction in cellular ATP levels by oligomycin was followed by induction of PGC1α expression (Figure 4c and d). The increase in PGC1α expression could be mediated by the increase in AMP levels and by activation of AMP-activated protein kinase, as reported by Lee et al.20 The induction of PGC1α expression is probably a compensative cellular response, in order to provide the energy demands of the cells. Indeed, it has been shown that transfection of NIH 3T3 fibroblasts with mouse cDNA for PGC1α leads to an increase in cellular ATP levels.38 Furthermore, PGC1α expression mediated the recovery of fibroblast cells from a partial chemical uncoupling of mitochondrial oxidative phosphorylation, with a decrease in ATP levels.39
In steatotic hepatocytes, the compensative effect of increased PGC1α activity is impaired. In contrast to the increase in PGC1α mRNA levels, its protein levels were significantly lower in CDE-fed mice (Figure 5a). Aoi et al40 found that the microRNA miR-696 is involved in the translational regulation of PGC1α and skeletal muscle metabolism in mice. It could be that CDE diet affects microRNAs in livers of mice, thus decreasing the translation of PGC1α mRNA to protein, yet posttranslational modifications may also be involved. In accordance to the reduced protein levels of PGC1α, reduced mRNA levels of NRF-1, TFAM and tfb2m were found in the fed state of CDE-fed mice. Moreover, the synergistic increase in PGC1α mRNA levels in steatotic livers after fasting did not lead to an increase in NRF-1 and TFAM mRNA levels, with a significant decrease in tfb2m expression when compared with control livers (Figures 5 and 6). This effect of CDE feeding on the biological activity of PGC1α was confirmed by in vivo ChiP analysis, which demonstrated a reduction in the binding PGC1α to the tfb2m promoter that contains NRF-1 and NRF-2 response elements (Figure 7). The decrease in PGC1α activity is not limited to the mitochondrial biogenesis pathway, as a significant decline in the binding of PGC1α to PEPCK promoter containing FOXO1 response element in steatotic livers was also observed.
CDE diet decreased the ability of PGC1α to bind and activate the tfb2m promoter, yet it had no effect on its binding and activation of the tfb1m promoter (Figure 7). Gleyzer et al25 reported that human TFB1M and TFB2M expression is regulated by the complexes of PGC1α with NRF-1 or NRF-2. However, it was suggested that the expression of the corresponding mouse genes tfb1m and tfb2m is mediated only by PGC1α–NRF-2 complex.41 Thus, it is possible that the regulation of tfb1m expression is mediated by additional transcription factors that compensate for the reduction in PGC1α biological activity. Nevertheless, although both human TFB1M and TFB2M interact directly with mitochondrial RNA polymerase to induce mtDNA replication and transcription, TFB2M is more active than TFB1M.24
In conclusion, impairment of mitochondrial biogenesis process was found in steatotic livers. However, the increase in PGC1α mRNA expression, which is most likely an attempt of the hepatocytes to compensate for the decrease in mitochondrial number, did not increase mitochondrial mass through the mitochondrial biogenesis pathway or PGC1α activity. Prolonged dysfunction of the mitochondrial biogenesis process may lead to increased oxidative stress and modify overall cellular function, which may contribute to progression of NAFLD to NASH. Finally, we propose the following scheme (Figure 8) for explaining the consequences of accumulation of fat in the liver and impaired PGC1α activity on NAFLD progression. To the best of our knowledge, this is the first evidence that directly links impaired biological activity of PGC1α with mitochondrial tissue content in NAFLD. We also demonstrate that the effect of steatosis on PGC1α activity influences other metabolic pathways that may also contribute to the progression of the disease.
References
Neuschwander-Tetri BA . Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005;330:326–335.
Wanless IR, Lentz JS . Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106–1110.
Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006;99:132–140.
Zeisel SH . Choline: critical role during fetal development and dietary requirements in adults. Annu Rev Nutr 2006;26:229–250.
Mato JM, Corrales FJ, Lu SC, et al. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J 2002;16:15–26.
Kulinski A, Vance DE, Vance JE . A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J Biol Chem 2004;279:23916–23924.
Akhurst B, Croager EJ, Farley-Roche CA, et al. A modified choline-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse liver. Hepatology 2001;34:519–522.
Knight B, Matthews VB, Akhurst B, et al. Liver inflammation and cytokine production, but not acute phase protein synthesis, accompany the adult liver progenitor (oval) cell response to chronic liver injury. Immunol Cell Biol 2005;83:364–374.
Tirosh O, Artan A, Aharoni-Simon M, et al. Impaired liver glucose production in a murine model of steatosis and endotoxemia: protection by inducible nitric oxide synthase. Antioxid Redox Signal 2010;13:13–26.
Ibdah JA, Perlegas P, Zhao Y, et al. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 2005;128:1381–1390.
Zhang D, Liu ZX, Choi CS, et al. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci USA 2007;104:17075–17080.
Bernardi P, Petronilli V, Di Lisa F, et al. A mitochondrial perspective on cell death. Trends Biochem Sci 2001;26:112–117.
Bonawitz ND, Rodeheffer MS, Shadel GS . Defective mitochondrial gene expression results in reactive oxygen species-mediated inhibition of respiration and reduction of yeast life span. Mol Cell Biol 2006;26:4818–4829.
Serviddio G, Sastre J, Bellanti F, et al. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Aspects Med 2008;29:22–35.
Staudinger JL, Lichti K . Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease. Mol Pharm 2008;5:17–34.
Estall JL, Kahn M, Cooper MP, et al. Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes 2009;58:1499–1508.
Finck BN, Kelly DP . PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006;116:615–622.
Puigserver P . Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes (Lond) 2005;29 (Suppl 1):S5–S9.
St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006;127:397–408.
Lee WJ, Kim M, Park HS, et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun 2006;340:291–295.
Mantena SK, King AL, Andringa KK, et al. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008;44:1259–1272.
Rantanen A, Jansson M, Oldfors A, et al. Downregulation of Tfam and mtDNA copy number during mammalian spermatogenesis. Mamm Genome 2001;12:787–792.
Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115–124.
Falkenberg M, Gaspari M, Rantanen A, et al. Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. Nat Genet 2002;31:289–294.
Gleyzer N, Vercauteren K, Scarpulla RC . Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol 2005;25:1354–1366.
Aronis A, Aharoni-Simon M, Madar Z, et al. Triacylglycerol-induced impairment in mitochondrial biogenesis and function in J774.2 and mouse peritoneal macrophage foam cells. Arch Biochem Biophys 2009;492:74–81.
Shilo S, Pardo M, Aharoni-Simon M, et al. Selenium supplementation increases liver MnSOD expression: molecular mechanism for hepato-protection. J Inorg Biochem 2008;102:110–118.
Villena JA, Hock MB, Chang WY, et al. Orphan nuclear receptor estrogen-related receptor alpha is essential for adaptive thermogenesis. Proc Natl Acad Sci USA 2007;104:1418–1423.
Bourdon A, Minai L, Serre V, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 2007;39:776–780.
Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579–H588.
Lu YC, Song J, Cho HY, et al. Cyclophilin a protects Peg3 from hypermethylation and inactive histone modification. J Biol Chem 2006;281:39081–39087.
Piantadosi CA, Carraway MS, Babiker A, et al. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ Res 2008;103:1232–1240.
Hashimoto T, Cook WS, Qi C, et al. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000;275:28918–28928.
Fleury C, Mignotte B, Vayssiere JL . Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002;84:131–141.
Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003;423:550–555.
Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001;413:131–138.
Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009;106:10853–10858.
Liang H, Bai Y, Li Y, et al. PGC-1alpha-induced mitochondrial alterations in 3T3 fibroblast cells. Ann N Y Acad Sci 2007;1100:264–279.
Rohas LM, St-Pierre J, Uldry M, et al. A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. Proc Natl Acad Sci USA 2007;104:7933–7938.
Aoi W, Naito Y, Mizushima K, et al. The microRNA miR-696 regulates PGC-1{alpha} in mouse skeletal muscle in response to physical activity. Am J Physiol Endocrinol Metab 2010;298:E799–E806.
Rantanen A, Gaspari M, Falkenberg M, et al. Characterization of the mouse genes for mitochondrial transcription factors B1 and B2. Mamm Genome 2003;14:1–6.
Acknowledgements
This study was supported by a grant no. 377/06 from the Israel Science Foundation to OT and ZM.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Laboratory Investigation website
Impaired mitochondrial biogenesis is due to attenuated activity of PPARγ-coactivator 1α in steatotic livers of C57BLl/6J mice. Inhibition of the effect of this coactivator leads to accumulation of fat droplets in the liver, increased damage to the mitochondria and contributes to the progression of non-alcoholic fatty liver disease.
Supplementary information
Rights and permissions
About this article
Cite this article
Aharoni-Simon, M., Hann-Obercyger, M., Pen, S. et al. Fatty liver is associated with impaired activity of PPARγ-coactivator 1α (PGC1α) and mitochondrial biogenesis in mice. Lab Invest 91, 1018–1028 (2011). https://doi.org/10.1038/labinvest.2011.55
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/labinvest.2011.55
Keywords
This article is cited by
-
Gluten worsens non-alcoholic fatty liver disease by affecting lipogenesis and fatty acid oxidation in diet-induced obese apolipoprotein E-deficient mice
Molecular and Cellular Biochemistry (2023)
-
Lactational delivery of Triclosan promotes non-alcoholic fatty liver disease in newborn mice
Nature Communications (2022)
-
Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators
Nature Reviews Gastroenterology & Hepatology (2019)
-
Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease
Archives of Pharmacal Research (2019)
-
Ablation of catalase promotes non-alcoholic fatty liver via oxidative stress and mitochondrial dysfunction in diet-induced obese mice
Pflügers Archiv - European Journal of Physiology (2019)